Nucynta Er
Pain, Acute Pain, Diabetic Neuralgia + 2 more
Treatment
6 Active Studies for Nucynta Er
Treatment for
Pain
What is Nucynta Er
Tapentadol
The Generic name of this drug
Treatment Summary
An opioid medication used to treat moderate to severe pain. This drug was approved by the FDA in 2008 and is used to help manage pain.
Nucynta
is the brand name
Nucynta Er Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Nucynta
Tapentadol
2009
46
Effectiveness
How Nucynta Er Affects Patients
Tapentadol is a synthetic painkiller that is 18 times weaker than morphine. It works by increasing the amount of a type of brain chemical (norepinephrine) and can be blocked by special antagonists like naloxone. Tapentadol does not affect the heart rate or rhythm.
How Nucynta Er works in the body
Tapendadol works by increasing the amount of the chemical norepinephrine in the body. It does this by binding to mu opioid receptors and blocking the reuptake of noradrenaline.
When to interrupt dosage
The suggested amount of Nucynta Er is contingent upon the identified condition, including intense, moderate Pain, Pain and Pain. The measure of dosage relies upon the method of administration (e.g. Tablet, extended release or Tablet, film coated, extended release - Oral) listed in the table beneath.
Condition
Dosage
Administration
Pain
100.0 mg, , 50.0 mg, 75.0 mg, 20.0 mg/mL, 150.0 mg, 200.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Oral, Solution, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release
Diabetic Neuralgia
100.0 mg, , 50.0 mg, 75.0 mg, 20.0 mg/mL, 150.0 mg, 200.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Oral, Solution, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release
Pain
100.0 mg, , 50.0 mg, 75.0 mg, 20.0 mg/mL, 150.0 mg, 200.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Oral, Solution, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release
Pain
100.0 mg, , 50.0 mg, 75.0 mg, 20.0 mg/mL, 150.0 mg, 200.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Oral, Solution, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release
Acute Pain
100.0 mg, , 50.0 mg, 75.0 mg, 20.0 mg/mL, 150.0 mg, 200.0 mg, 250.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Solution - Oral, Solution, Tablet, extended release, Tablet, extended release - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release
Warnings
Nucynta Er Contraindications
Condition
Risk Level
Notes
Asthma
Do Not Combine
Intestinal Pseudo-Obstruction
Do Not Combine
Hypercapnia
Do Not Combine
Pulse Frequency
Do Not Combine
Respiratory Function Impaired
Do Not Combine
Gastrointestinal obstruction
Do Not Combine
Mental Depression
Do Not Combine
There are 20 known major drug interactions with Nucynta Er.
Common Nucynta Er Drug Interactions
Drug Name
Risk Level
Description
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
Major
The risk or severity of adverse effects can be increased when Tapentadol is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Azelastine
Major
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Benmoxin
Major
The risk or severity of adverse effects can be increased when Tapentadol is combined with Benmoxin.
Brofaromine
Major
The risk or severity of adverse effects can be increased when Tapentadol is combined with Brofaromine.
Caroxazone
Major
The risk or severity of adverse effects can be increased when Tapentadol is combined with Caroxazone.
Nucynta Er Toxicity & Overdose Risk
Tests in rabbits, mice, and rats have shown the toxic dose of this drug to be 3200mg/kg, 300mg/kg, and 980mg/kg respectively. The most common side effects reported in patients taking this drug are dizziness, nausea, vomiting, drowsiness, and headaches.
Nucynta Er Novel Uses: Which Conditions Have a Clinical Trial Featuring Nucynta Er?
Presently, one clinical trial is assessing the viability of Nucynta Er in providing relief from acute, moderate Pain and Pain.
Condition
Clinical Trials
Trial Phases
Pain
0 Actively Recruiting
Acute Pain
0 Actively Recruiting
Pain
0 Actively Recruiting
Pain
0 Actively Recruiting
Diabetic Neuralgia
4 Actively Recruiting
Phase 1, Phase 2, Phase 3
Nucynta Er Reviews: What are patients saying about Nucynta Er?
5
Patient Review
6/29/2017
Nucynta Er for Chronic Pain
5
Patient Review
8/11/2017
Nucynta Er for Chronic Pain
5
Patient Review
11/1/2017
Nucynta Er for Chronic Pain
5
Patient Review
8/11/2017
Nucynta Er for Chronic Pain
5
Patient Review
11/1/2017
Nucynta Er for Chronic Pain
5
Patient Review
6/29/2017
Nucynta Er for Chronic Pain
4.3
Patient Review
8/11/2017
Nucynta Er for Chronic Pain
4.3
Patient Review
8/11/2017
Nucynta Er for Chronic Pain
4
Patient Review
10/25/2016
Nucynta Er for Chronic Pain
4
Patient Review
10/25/2016
Nucynta Er for Chronic Pain
3.3
Patient Review
10/27/2022
Nucynta Er for Chronic Pain
3.3
Patient Review
9/6/2016
Nucynta Er for Chronic Pain
3.3
Patient Review
10/27/2022
Nucynta Er for Chronic Pain
3.3
Patient Review
9/6/2016
Nucynta Er for Chronic Pain
2.7
Patient Review
1/2/2019
Nucynta Er for Chronic Pain
2.7
Patient Review
1/2/2019
Nucynta Er for Chronic Pain
1
Patient Review
6/28/2017
Nucynta Er for Severe Pain
1
Patient Review
5/5/2019
Nucynta Er for Chronic Pain
1
Patient Review
4/28/2018
Nucynta Er for Chronic Pain
1
Patient Review
6/28/2017
Nucynta Er for Severe Pain
1
Patient Review
5/5/2019
Nucynta Er for Chronic Pain
1
Patient Review
4/28/2018
Nucynta Er for Chronic Pain
Patient Q&A Section about nucynta er
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How long does it take for Nucynta ER to start working?
"When will I start to feel better?
You should notice some pain relief within 3-6 hours of taking extended release tapentadol. With continued twice daily dosing, a steady amount of drug will be present in the blood supply and help achieve continuous pain relief."
Answered by AI
What are the side effects of Nucynta ER?
"The following side effects may occur: nausea, vomiting, constipation, dizziness, drowsiness, dry mouth, increased sweating, or tiredness. To prevent constipation, eat dietary fiber, drink enough water, and exercise. To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position."
Answered by AI
How often can you take nucynta ER?
"The recommended starting dose for patients who are not opioid tolerant is NUCYNTA ER 50 mg orally twice daily. Use of higher starting doses in patients who are not opioid tolerant can cause fatal respiratory depression."
Answered by AI
How does nucynta ER make you feel?
"Serious breathing problems may be more likely in older adults and in those who are debilitated or have wasting syndrome or chronic breathing disorders. Nucynta ER may cause common side effects including: constipation, nausea, vomiting, stomach pain; headache, feeling tired; or."
Answered by AI